valproic acid and meropenem

Meropenem reduces valproic acid concentrations by increasing its clearance and decreasing its absorption. It inhibits the hydrolysis of valproic acid glucuronide in the gut, reducing enterohepatic recirculation, and increases renal clearance through inhibition of renal tubular reabsorption. This is a pharmacokinetic interaction at the level of drug transport and metabolism.

Serum valproic acid concentrations can fall by more than 70% within 24 to 48 hours of starting meropenem, leading to loss of seizure control, breakthrough seizures, or status epilepticus. The effect is reversible after discontinuation of the antibiotic, but the risk of harm is significant.

Avoid concurrent use of meropenem and valproic acid. Select an alternative antibiotic if possible. If meropenem is unavoidable, consider an alternative anticonvulsant. If no alternative exists, monitor valproic acid concentrations closely and adjust the dose, although this is frequently ineffective. Seek specialist advice and warn patients to report any increase in seizure frequency.

This interaction is well established in the medical literature, with numerous case reports and clinical studies showing a rapid and substantial reduction in valproic acid levels. It is documented in product labelling and major drug interaction databases, and is widely accepted as clinically significant.